New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2013
05:55 EDTGLW, GLW, GSK, GSK, PFE, PFE, BAYRY, BAYRY, LLY, LLY, SNY, SNY, MNTA, MNTA, ONXX, ONXX, AMGN, AMGN, MRK, MRK, CBST, CBST, BIIB, BIIB, SHPG, SHPGBoston Biotech Conferences to host a conference
BD Biotech Conference is being held in Boston on April 2-3.
News For GLW;BIIB;CBST;MRK;AMGN;ONXX;MNTA;SNY;LLY;BAYRY;PFE;GSK;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 15, 2015
14:31 EDTGSKMylan launches generic Epivir-HBV tablets
Mylan (MYL) announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's (GSK) Epivir-HBV. Mylan received final approval from the U.S. FDA for its Abbreviated New Drug Application for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. Lamivudine Tablets, 100 mg, had U.S. sales of approximately $18.1M for the 12 months ending September 30, 2014, according to IMS Health. Currently, Mylan has 284 ANDAs pending FDA approval representing $109.1B in annual brand sales, according to IMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3B in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.
11:20 EDTMRK, LLY, PFEGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
10:00 EDTGLW, LLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:36 EDTGSKOncoMed enrolls first biomarker-selected patient in Notch1 antibody Phase trial
Subscribe for More Information
07:59 EDTPFE, ONXX, MRK, BAYRY, AMGNAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
07:29 EDTBIIBOutlook for Biogen trials positive , says RBC Capital
Subscribe for More Information
07:07 EDTLLYEli Lilly upgraded at Goldman
As previously reported, Goldman upgraded Eli Lilly to Neutral from Sell. The firm upgraded shares based on new product launches and pipeline assets, and cost reductions. Price target is $70.
06:45 EDTGLWCorning upgraded to Overweight from Neutral at JPMorgan
Subscribe for More Information
06:44 EDTLLYEli Lilly upgraded to Neutral from Sell at Goldman
Subscribe for More Information
January 14, 2015
08:34 EDTMRKMerck and Practice Fusion's health vaccine initiative shows positive results
Merck and Practice Fusion announced the results of a recent collaboration designed to improve public health outcomes through a Population Health Management program for adult vaccines. Launched in April, the program contributed to a statistically significant relative increase in recorded vaccinations among eligible patients on Practice Fusion's EHR platform. During the four-month test period, Practice Fusion observed a 73% relative increase in recorded vaccinations in test versus control patients.
07:05 EDTBIIBIsis Pharmaceuticals earns $7M from Biogen for advancing muscular atrophy study
Subscribe for More Information
January 13, 2015
17:37 EDTSHPGShire targets $10B in organic product sales by 2020
Subscribe for More Information
13:09 EDTBIIBBiogen CEO says company has strengthened R&D, to stay active in M&A
Subscribe for More Information
12:55 EDTAMGNAmgen repeats FY15 adjusted EPS view $9.05-$9.40, consensus $9.29
Subscribe for More Information
12:40 EDTLLY, AMGNAmgen off highs after Express Scripts CEO talks PCSK9 costs
Subscribe for More Information
09:44 EDTMRKMerck makes $50M equity investment in Moderna under collaboration
Subscribe for More Information
08:08 EDTLLY, MRKEli Lilly, Merck enter collaborationa greement to evaluate Keytruda, compounds
Merck (MRK) and Eli Lilly and Company (LLY) announced an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Merck will conduct a Phase 2 study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer. This study is currently enrolling. Lilly will conduct a multiple-arm Phase 1/2 study examining the combination of ramucirumab with pembrolizumab in multiple tumors. This study is anticipated to begin in 2015. Lilly will conduct a Phase 1/2 study examining the combination of necitumumab with pembrolizumab in NSCLC. This study is anticipated to begin in 2015. The agreement is between Lilly and Merck, through a subsidiary. Additional details of the collaboration were not disclosed.
08:05 EDTLLYBristol-Myers Eli Lilly enter clinical collaboration pact for Opdivo combo
Subscribe for More Information
08:04 EDTCBSTCubist announces withdrawal of CVRs from Nasdaq Global Select Market
Cubist Pharmaceuticals announced that it will voluntarily withdraw the contingent value rights, or CVRs, it issued under a Contingent Value Rights Agreement dated October 24, 2013 from listing on the NASDAQ Global Select Market on February 2, 2015, contemporaneously with their redemption. The CVRs are currently listed under the symbol CBSTZ. Cubist is withdrawing the CVRs from listing in connection with the Failure Purchase of all outstanding CVRs on February 2, 2015 in accordance with the terms of the CVR Agreement. On February 2, 2015, all outstanding CVRs will be purchased by Cubist and cancelled. Cubist has not arranged, nor does it intend to arrange, for the listing of the CVRs on another securities exchange or for quotation on any other quotation medium. Cubist currently anticipates that it will file a Form 25 with the U.S. SEC on January 23, 2015 to commence the delisting process. It is expected that the delisting will take effect on February 2, 2015.
07:42 EDTAMGNJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use